SNGXSoligenix Inc

Today’s trading session saw aggressive momentum rotate back into speculative growth, biotech, AI infrastructure, and emerging technology names as traders hunted for high-volatility opportunities heading into the closing bell and after-hours session. Several low-float biotech and technology stocks experienced sharp increases in volume following clinical updates, financing announcements, analyst attention, and broader retail speculation. $NTHI, $QBTT, $ASTI, $MNTS, $APPS, $SNGX, $AMSS

Soligenix shares are also poised to break above the 100-day moving average for the first time in a month, following a four-session rally.

Soligenix shares surged 72.32% in after-hours trading following rapid Bundibugyo virus vaccine development announcement.read more...

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo PR Newswire PRINCETON, N.J., May 26, 2026 Thermostability, immunogenicity and efficacy data against related...

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results Soligenix Announces Recent Updates and First Quarter 2026 Financial Results PR Newswire PRINCETON, N.J., May 8, 2026...

On Tuesday, LCID stock slipped 1%, marking its fifth straight session of losses, while SNGX plunged 70% and SRAD fell 11%.

An independent committee recommended stopping Soligenix’s late-stage trial to treat lymphoma due to a lack of effectiveness.

Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.read more...

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63...